Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

William G. Wierda, Susan O'Brien, Xuemei Wang, Stefan Faderl, Alessandra Ferrajoli, Kim Anh Do, Guillermo Garcia-Manero, Jorge Cortes, Deborah Thomas, Charles A. Koller, Jan A. Burger, Susan Lerner, Ellen Schlette, Lynne Abruzzo, Hagop M. Kantarjian, Michael J. Keating

Research output: Contribution to journalArticle

Abstract

Purpose: The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL. Patients and Methods: Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram - a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment. Results: There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status. Conclusion: We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.

Original languageEnglish (US)
Pages (from-to)4088-4095
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number31
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Fluorescence In Situ Hybridization
Lymph Nodes
Nomograms
Mutation
L-Lactate Dehydrogenase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K. A., ... Keating, M. J. (2011). Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 29(31), 4088-4095. https://doi.org/10.1200/JCO.2010.33.9002

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. / Wierda, William G.; O'Brien, Susan; Wang, Xuemei; Faderl, Stefan; Ferrajoli, Alessandra; Do, Kim Anh; Garcia-Manero, Guillermo; Cortes, Jorge; Thomas, Deborah; Koller, Charles A.; Burger, Jan A.; Lerner, Susan; Schlette, Ellen; Abruzzo, Lynne; Kantarjian, Hagop M.; Keating, Michael J.

In: Journal of Clinical Oncology, Vol. 29, No. 31, 01.11.2011, p. 4088-4095.

Research output: Contribution to journalArticle

Wierda, WG, O'Brien, S, Wang, X, Faderl, S, Ferrajoli, A, Do, KA, Garcia-Manero, G, Cortes, J, Thomas, D, Koller, CA, Burger, JA, Lerner, S, Schlette, E, Abruzzo, L, Kantarjian, HM & Keating, MJ 2011, 'Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia', Journal of Clinical Oncology, vol. 29, no. 31, pp. 4088-4095. https://doi.org/10.1200/JCO.2010.33.9002
Wierda, William G. ; O'Brien, Susan ; Wang, Xuemei ; Faderl, Stefan ; Ferrajoli, Alessandra ; Do, Kim Anh ; Garcia-Manero, Guillermo ; Cortes, Jorge ; Thomas, Deborah ; Koller, Charles A. ; Burger, Jan A. ; Lerner, Susan ; Schlette, Ellen ; Abruzzo, Lynne ; Kantarjian, Hagop M. ; Keating, Michael J. / Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 31. pp. 4088-4095.
@article{7b7a2babb3c441ed875b993b590a52c7,
title = "Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia",
abstract = "Purpose: The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL. Patients and Methods: Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram - a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment. Results: There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status. Conclusion: We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.",
author = "Wierda, {William G.} and Susan O'Brien and Xuemei Wang and Stefan Faderl and Alessandra Ferrajoli and Do, {Kim Anh} and Guillermo Garcia-Manero and Jorge Cortes and Deborah Thomas and Koller, {Charles A.} and Burger, {Jan A.} and Susan Lerner and Ellen Schlette and Lynne Abruzzo and Kantarjian, {Hagop M.} and Keating, {Michael J.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1200/JCO.2010.33.9002",
language = "English (US)",
volume = "29",
pages = "4088--4095",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

AU - Wierda, William G.

AU - O'Brien, Susan

AU - Wang, Xuemei

AU - Faderl, Stefan

AU - Ferrajoli, Alessandra

AU - Do, Kim Anh

AU - Garcia-Manero, Guillermo

AU - Cortes, Jorge

AU - Thomas, Deborah

AU - Koller, Charles A.

AU - Burger, Jan A.

AU - Lerner, Susan

AU - Schlette, Ellen

AU - Abruzzo, Lynne

AU - Kantarjian, Hagop M.

AU - Keating, Michael J.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Purpose: The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL. Patients and Methods: Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram - a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment. Results: There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status. Conclusion: We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.

AB - Purpose: The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL. Patients and Methods: Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram - a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment. Results: There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status. Conclusion: We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.

UR - http://www.scopus.com/inward/record.url?scp=80755127112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755127112&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.9002

DO - 10.1200/JCO.2010.33.9002

M3 - Article

C2 - 21969505

AN - SCOPUS:80755127112

VL - 29

SP - 4088

EP - 4095

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -